000 03779nam a22004335i 4500
999 _c127507
_d127507
_x1
001 127507
003 ES-MaUEC
005 20240119142143.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200930s2020 si | s |||| 0|eng d
020 _a9789811575860
024 7 _a10.1007/978-981-15-7586-0
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC271.C5
_b2020 EB
245 0 0 _aDrug Targets in Cellular Processes of Cancer :
_bFrom Nonclinical to Preclinical Models
_cedited by Hardeep Singh Tuli
250 _aFirst edition 2020
264 1 _aSingapore
_bSpringer Singapore :
_bImprint: Springer
_c2020
300 _a1 recurso en línea (XIII, 228 páginas)
_b28 ilustraciones, 26 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aBiomedical and Life Sciences (SpringerNature-11642)
490 0 _aBiomedical and Life Sciences (SpringerNature-43708)
505 0 _aChapter 1. History of oncotherapies in cancer biology -- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs -- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer -- Chapter 4. Apoptotic cell death: important cellular process as chemotherapeutic target -- Chapter 5. Regulatory roles of autophagy in cancer -- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances -- Chapter 7. Inflammatory mediators: Potential drug targets in cancer -- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer -- Chapter 10. Metastasis: A major driver of cancer pathogenesis -- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.
520 3 _aThis book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
988 _aSpringer_BiomedLife_13102020
650 4 _aCáncer
_xQuimioterapia
_9674463
650 7 _2embne
_9174085
_aCáncer
_xTratamiento
700 1 _aTuli, Hardeep Singh
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink
776 0 8 _iPrinted edition:
_z9789811575853
776 0 8 _iPrinted edition:
_z9789811575877
776 0 8 _iPrinted edition:
_z9789811575884
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-15-7586-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b01/2021
_dz
_eIG
_zSI